Pharmahuasca
Pharmahuasca is a pharmaceutical version of the entheogenic brew ayahuasca. Traditional ayahuasca is made by brewing the MAOI-containing Banisteriopsis caapi vine with a DMT-containing plant, such as Psychotria viridis. Pharmahuasca refers to a similar combination that uses a pharmaceutical MAOI instead of a plant.
For pharmahuasca, 50 mg N,N-DMT and 100 mg harmaline is usually the recommended dosage per person. However, combinations of 50 mg harmaline, 50 mg harmine, and 50 mg, N,N-DMT have been tested with success. As a rule, the fewer the β-carbolines, the less nausea; the more DMT, the more spectacular the visions. The constituents are put into separate gelatin capsules. The capsules with harmaline/harmine are swallowed first and the capsules containing DMT are taken 15 to 20 minutes later. Purely synthetic MAO inhibitors can be used in place of harmaline and harmine, although caution must be taken when choosing an MAOI.[1] The use of Moclobemide, a reversible inhibitor of monoamine oxidase-A (RIMA), has been recorded and is safer than older irreversible MAOIs (such as isocarboxazid) due to its significantly shorter and more selective effects (although it still exhibits a wide range of dangerous drug-drug interactions).[2][3]
See also
External links
References
- ^ Ott J. Ayahuasca Analogues: Pangaen Entheogens. Natural Products Co.. 1994. 34
- ^ Kaasik, Helle; Souza, Rita C. Z.; Zandonadi, Flávia S.; Tófoli, Luís Fernando; Sussulini, Alessandra (2020-09-08). "Chemical Composition of Traditional and Analog Ayahuasca". Journal of Psychoactive Drugs: 1–11. doi:10.1080/02791072.2020.1815911. ISSN 2159-9777. PMID 32896230.
- ^ Ruffell, Simon; Netzband, Nige; Bird, Catherine; Young, Allan H.; Juruena, Mario F.; Ruffell, Simon; Netzband, Nige; Bird, Catherine; Young, Allan H.; Juruena, Mario F. (2020-07-03). "The pharmacological interaction of compounds in ayahuasca: a systematic review". Brazilian Journal of Psychiatry. 42 (6): 646–656. doi:10.1590/1516-4446-2020-0884. ISSN 1516-4446.